News | Congenital Heart | February 05, 2018

Stem Cell Therapy May Offer Treatment for Rare Congenital Cardiac Defect

Children’s Hospital Los Angeles part of first clinical trial to use umbilical cord blood to delay or even prevent hypoplastic left heart syndrome

Stem Cell Therapy May Offer Treatment for Rare Congenital Cardiac Defect

February 5, 2018 — Children's Hospital Los Angeles announced participation in the first-ever clinical trial using stem cells from umbilical cord blood to delay or even prevent heart failure in children born with a rare congenital heart defect leaving them with half a heart.

The Phase I study is part of a multi-center collaboration dedicated to employing innovative therapies to improve outcomes for children with hypoplastic left heart syndrome (HLHS), a congenital heart defect in which the left ventricle is severely underdeveloped. The HLHS Consortium, launched at the Mayo Clinic in Minnesota in 2017, involves four regional centers.

"We're proud to be part of this select group of institutions," said Vaughn Starnes, M.D., co-director of the Heart Institute at CHLA and chair, Department of Surgery, at the Keck School of Medicine of the University of Southern California. "As a leading center for medical and surgical treatments for HLHS, we want to be at the forefront of the next transformative therapy for treating this complex condition."

In addition to the Mayo Clinic, other Consortium members include Children's Hospital of Philadelphia and Minnesota Children's Hospital.

"It is very exciting that Children’s Hospital Los Angeles has joined the HLHS consortium. It means that individuals with HLHS now have more options when it comes to participating in groundbreaking clinical trials and other research," said Timothy Nelson, M.D., Ph.D., director of the Mayo Clinic's Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome.

In HLHS, the left ventricle of the heart cannot pump oxygen-rich blood from the lungs to the rest of the body. Without surgical intervention, HLHS is fatal. Children undergo a series of three surgeries in their first three years to make the right ventricle the heart's main pumping chamber and improve blood flow.

This first-of-its-kind clinical trial combines pioneering surgical techniques with regenerative medicine. "This is one of the earliest efforts at harnessing the power of stem cell technology for the care of children with a serious cardiac disease," said Ram Kumar Subramanyan, M.D., Ph.D., a cardiothoracic surgeon who is heading the HLHS study in CHLA's Heart Institute.

CHLA first performed HLHS surgery in 1992. In the decades since, doctors have found that as children with HLHS reach adolescence, their reconstructed hearts are deteriorating. For some, that means heart failure and the need for a heart transplant. "We are looking for novel approaches to this vexing problem," said Starnes.

At the time of delivery, newborns enrolled in the study will have their umbilical cord blood collected and sent to the Mayo Clinic where the stem cells are removed. Within a few hours of birth, the baby arrives at CHLA and has the first HLHS surgery 2 to 5 days later.

The second open-heart surgery, the Glenn procedure, takes place at about six months of age, when the baby's own stem cells are injected back into their heart. The hypothesis is that stem cells will stimulate the heart muscle to grow during the critical first year of life, when cardiac cells still have the ability to proliferate. At about three years of age, the child then has the third surgery, the Fontan procedure.

All children in the study will be followed long-term, as doctors look for signs that their hypothesis is working to produce a stronger heart for these at-risk children.

Together, the HLHS Consortium members hope to recruit about 20 children for the Phase I umbilical cord blood study. CHLA investigators already have enrolled several families. Find out more about the study at CHLA here.

Funding for CHLA’s participation in the Consortium has been provided in part by the Taglyan Family.

For more information: www.chla.org

 


Related Content

News | Congenital Heart

March 31, 2025 — AGEPHA Pharma USA, LLC, has highlighted clinical data that provides new information about how low-dose ...

Home March 31, 2025
Home
News | Congenital Heart

March 17, 2025 — Being born with a heart defect may be associated with an increased cancer risk for babies and their ...

Home March 17, 2025
Home
News | Congenital Heart

September 12, 2023 — UCLA-led research finds that among adult congenital heart disease (CHD) transplant recipients ...

Home September 12, 2023
Home
News | Congenital Heart

August 31, 2023 — The European Society of Cardiology (ESC) Guidelines on cardiomyopathies are published online in ...

Home August 31, 2023
Home
News | Congenital Heart

July 3, 2023 — Researchers at the UNC School of Medicine, UNC McAllister Heart Institute, and the UNC Lineberger ...

Home July 03, 2023
Home
News | Congenital Heart

February 24, 2023 — Medtronic today announced the relaunch of its Harmony Transcatheter Pulmonary Valve (TPV) System, a ...

Home February 24, 2023
Home
News | Congenital Heart

December 30, 2022 — The Smidt Heart Institute at Cedars-Sinai welcomes four new specialists to its Department of ...

Home December 30, 2022
Home
News | Congenital Heart

November 2, 2022 — Researchers have developed a three-dimensional model that shows how exposure to cadmium might lead to ...

Home November 02, 2022
Home
News | Congenital Heart

October 3, 2022 — A new ‘ECHO lab’ at Memorial Hospital West is benefiting patients that may have heart disease and the ...

Home October 03, 2022
Home
News | Congenital Heart

August 2, 2022 — About one percent of the world population is born with a congenital heart defect, which affects about ...

Home August 02, 2022
Home
Subscribe Now